JOHN HOPE FRANKLIN CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1838-01-01

Employees: 5K

Market Cap: -

Website: http://www.duke.edu

Clinical Trials

Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Recurrent Adult Brain Tumor

Interventions: Drug: Gliadel wafers in combination with O6-benzylguanine

First Posted Date: 2006-08-15

Last Posted Date: 2014-07-10

Lead Sponsor: Duke University

Target Recruit Count: 52

Registration Number: NCT00362921

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Drug-Induced Liver Injury (DILI) Network Retrospective

Recruiting

Conditions: Drug Induced Liver Injury

First Posted Date: 2006-08-04

Last Posted Date: 2025-04-20

Lead Sponsor: Duke University

Target Recruit Count: 400

Registration Number: NCT00360646

Locations: 🇺🇸
University of Southen California, Los Angeles, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
NIH Clinical Site, Bethesda, Maryland, United States

and more 3 locations

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: hydroxyurea
Drug: imatinib mesylate

First Posted Date: 2006-07-20

Last Posted Date: 2013-01-18

Lead Sponsor: Duke University

Target Recruit Count: 21

Registration Number: NCT00354913

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-07-20

Last Posted Date: 2013-03-28

Lead Sponsor: Duke University

Target Recruit Count: 65

Registration Number: NCT00354068

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: bevacizumab
Drug: irinotecan
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2006-07-14

Last Posted Date: 2014-07-22

Lead Sponsor: Duke University

Target Recruit Count: 20

Registration Number: NCT00352521

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

DILIN - Prospective Study

Recruiting

Conditions: Liver Diseases

First Posted Date: 2006-06-29

Last Posted Date: 2025-04-20

Lead Sponsor: Duke University

Target Recruit Count: 4000

Registration Number: NCT00345930

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 3 locations

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Drug: lyso-thermosensitive liposomal doxorubicin(Thermodox)
Procedure: hyperthermia treatment

First Posted Date: 2006-06-29

Last Posted Date: 2016-03-22

Lead Sponsor: Duke University

Target Recruit Count: 29

Registration Number: NCT00346229

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Quit Smoking Program for Lung Cancer Patients' Families (The Family Ties Project)

Not Applicable

Completed

Conditions: Smoking Cessation

First Posted Date: 2006-06-29

Last Posted Date: 2014-07-25

Lead Sponsor: Duke University

Target Recruit Count: 496

Registration Number: NCT00345891

Locations: 🇺🇸
UNC Chapel Hill Multidisciplinary Thoracic Oncology Program, Chapel Hill, North Carolina, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute Thoracic Oncology Program, Tampa, Florida, United States
🇺🇸
Duke University Medical Center Thoracic Oncology Program, Durham, North Carolina, United States

and more 1 locations

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

Phase 2

Completed

Conditions: Affective Disorders

Interventions: Drug: Sertraline
Drug: Ziprasidone
Drug: Haloperidol

First Posted Date: 2006-06-21

Last Posted Date: 2014-08-19

Lead Sponsor: Duke University

Target Recruit Count: 72

Registration Number: NCT00340379

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇪🇬
Alexandria University, Alexandria, Egypt
🇮🇳
National Institute of Mental Health and Neuroscience, Bangalore, India

Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression

Not Applicable

Completed

Conditions: Depression

First Posted Date: 2006-06-20

Last Posted Date: 2013-08-09

Lead Sponsor: Duke University

Target Recruit Count: 131

Registration Number: NCT00339066

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy